SCHEMBL982630

SCHEMBL982630

O=C(O)c1cc2ccc(O)c(O)c2oc1=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 11/20 0.72
MAOA P21397 2/20 0.66
HPGD P15428 3/20 0.62
ALDH1A1 P00352 2/20 0.62
LMNA P02545 2/20 0.62
ADORA3 P0DMS8 3/20 0.58
ADORA2A P29274 3/20 0.58
ADORA1 P30542 3/20 0.58
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA3 P07451 2/20 0.54
CA4 P22748 2/20 0.54
CA6 P23280 2/20 0.54
CA5A P35218 2/20 0.54
CA7 P43166 2/20 0.54
CA9 Q16790 2/20 0.54
CA14 Q9ULX7 2/20 0.54
CA5B Q9Y2D0 2/20 0.54
CA2 P00918 1/20 0.54
POLB P06746 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11053124 0.85 ADORA2A (0.53) GPR35MAOAHPGDALDH1A1LMNA
SCHEMBL31114119 0.83 MAOA (0.62) GPR35MAOAHPGDALDH1A1LMNA
SCHEMBL22129780 0.83 MAOA (0.72) GPR35MAOAHPGDALDH1A1LMNA
SCHEMBL9587791 0.83 GPR35 (0.77) GPR35MAOAHPGDALDH1A1LMNA
SCHEMBL14924889 0.81 MAOA (0.59) GPR35MAOAHPGDALDH1A1LMNA
SCHEMBL22132743 0.80 MAOA (0.56) GPR35MAOAHPGDALDH1A1LMNA
SCHEMBL22132756 0.80 MAOA (0.65) GPR35MAOAHPGDALDH1A1LMNA
SCHEMBL30969182 0.80 ADORA2A (0.48) GPR35MAOAHPGDALDH1A1LMNA
SCHEMBL7066529 0.80 GPR35 (0.77) GPR35MAOAHPGDALDH1A1LMNA
SCHEMBL30969178 0.80 MAOA (0.65) GPR35MAOAHPGDALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119707902-B Preparation method of daphnetin 吉林大学第一医院 2025-05-30 CN disclosed
CN-119707902-A Preparation method of daphnetin 吉林大学第一医院 2025-03-28 CN disclosed
US-8642788-B2 Activators of executioner procaspases 3, 6 and 7 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-02-04 US disclosed
CN-101965189-A Activators of pro-caspase 3, 6 and 7 UNIV CALIFORNIA 2011-02-02 CN disclosed
US-20110021522-A1 ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-01-27 US disclosed
EP-2237784-A1 ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 The Regents of the University of California (US) 2010-10-13 EP disclosed
WO-2009089508-A1 ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-07-16 WO disclosed
EP-0846127-A1 ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY Novartis AG (CH) 1998-06-10 EP disclosed
WO-1997008193-A1 ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY NOVARTIS AG (CH) 1997-03-06 WO disclosed
US-4468394-A Cephalosporin compounds EISAI CO., LTD. (JP) 1984-08-28 US disclosed
US-4415567-A A 7B-CHROMONE-3-CARBOXAMIDO-2-/4-HYDROXY PHENYL/ACETAMIDO-2-CEPHEM DERIVATIVE EISAI CO., LTD. (JP) 1983-11-15 US disclosed
EP-0062328-A2 Novel penicillin and cephalosporin compounds, a process for preparing the same and antibacterial composition containing the novel compounds Eisai Co., Ltd. (JP) 1982-10-13 EP disclosed
US-4344944-A 7-α-methoxycephalosporin derivatives, and antibacterial drugs onctaining the same EISAI CO., LTD. (JP) 1982-08-17 US disclosed
US-4285940-A ANTIBIOTICS EISAI CO., LTD. (JP) 1981-08-25 US disclosed
US-4285941-A ANTIBIOTICS EISAI CO., LTD. (JP) 1981-08-25 US disclosed
US-4285939-A ANTIBIOTICS EISAI CO., LTD. (JP) 1981-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021522-A1 ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 CASP7, CASP3, CASP6 GPR35 4234/4885MAOA 2101/4885HPGD 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.